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Histone deacetylase inhibitors have progressed rapidly from the laboratory to clinical testing. This review highlights the promising data
for their combination with a wide range of established and novel anticancer agents and discusses the mechanisms that underpin these
interactions.
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Histone deacetylase inhibitors (HDIs) have progressed rapidly
from the laboratory to clinical testing as novel anticancer agents,
culminating in the approval of SAHA (Vorinostat, Merck,
Whitehouse Station, NJ, USA) for the treatment of recurrent
cutaneous T-cell lymphoma. However, despite their promising
activity in pre-clinical models, HDIs have demonstrated only
modest antitumour activity in initial clinical trials in solid
malignancies. In this review, we will discuss current findings to
support the hypothesis that in most scenarios, combination with
other therapeutic modalities will be required to optimise efficacy
and current evidence for the molecular mechanisms that underpin
potential combinations.
HDIs – STRUCTURE AND MECHANISM OF ACTION
Histone deacetylase (HDAC) enzymes counter the activity of
histone acetyltransferases by inducing hydrolysis of the e-amino
acetyl moiety on specific acetylated lysine residues within core
histones (Figure 1A and B). Histone acetylation participates in
transcriptional regulation in concert with other epigenetic events
such as DNA and histone methylation. Histone deacetylase
inhibitors induce accumulation of acetylated histones, resulting
in the relaxation of chromatin structure and promoting access to
transcriptional machinery. Surprisingly, these transcriptional
effects are relatively selective, only affecting around 3–10% of
the transcriptome, with both the induction and repression of gene
expression targets. There may be a common gene expression
signature in response to HDIs. For example, reversal of epigenetic
silencing of the p21
WAF1/CIP1 cyclin-dependent kinase inhibitor is
observed in various cancer cell types and for all HDIs. However,
cell-specific effects such as modulation of nuclear hormone
receptors or cell signalling pathways may vary in biological
importance in particular cancer types, which may be relevant for
combination strategies.
Although the modulation of transcription through histone
modification serves as a useful paradigm, the mechanisms that
mediate the anticancer effects of HDIs are more complex, with
many non-histone targets identified (Figure 2).
There are multiple HDIs in clinical development and key
representatives are shown in Figure 1C. These molecules are
structurally diverse, but with the common feature of employing a
chemical ‘war-head’ active site that chelates the zinc atom in the
active site of Class I and/or II HDACs, thereby blocking enzyme
activity. With the exception of very simple aliphatic acids such as
valproic acid (VPA), these molecules conform to a common
pharmacophore (Figure 1C), comprising a ‘linker’ mimicking a
lysine side chain, and a ‘cap’ structure of variable size that makes
additional interactions around the rim of the enzyme active site.
HDI COMBINATIONS WITH CYTOTOXIC
CHEMOTHERAPY
In an attempt to find a niche for HDIs, they have been tested in
combination with a variety of conventional cytotoxic chemo-
therapeutic agents. Pre-clinical data in multiple cancer cell lines
(including breast, ovarian, pancreatic, colon, non-small cell lung,
prostate, thyroid, hepatocellular and oral squamous cell carcino-
mas and melanoma) have shown the potentiation by HDIs of the
effects of topoisomerase I inhibitors (camptothecin, irinotecan,
topotecan) topoisomerase II inhibitors (epirubicin, doxorubicin,
etoposide, mitoxantrone) and other DNA-damaging agents (cis-
platin, oxaliplatin, bleomycin). In vitro, synergistic induction of
apoptosis is seen when HDIs are combined with epirubicin in
breast cancer cells and with etoposide or cisplatin in melanoma
cells (Marchion et al, 2005; Valentini et al, 2007). In vivo
potentiation of epirubicin has been confirmed in breast cancer
xenograft models (Marchion et al, 2005). Subsequently, a phase I
clinical trial of VPA combined with epirubicin showed a 22%
partial response rate in multiply pretreated solid malignancies
(Munster et al, 2007). It is worth noting that these investigators
began VPA 48h before infusion of epirubicin on each cycle to
attempt to exploit synergism seen with this sequencing approach
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Figure 2 The mechanisms of action of HDIs are varied with the modification of acetylation status of many non-histone proteins as well as core histones,
resulting in a wide range of biological effects.
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Figure 1 (A) Structure of core histone with sites of N-terminal lysine side-chain acetylation shown. (B) Histone deacetylase (HDAC) enzymes counter
the activity of histone acetyltransferases (HAT) by inducing hydrolysis of the e-amino acetyl moiety on specific acetylated lysine residues. (C) Structure of
HDIs in clinical development, demonstrating conformation to a common pharmacophore.
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toxicity was predominantly neurovestibular (including dizziness,
confusion and hearing loss) or gastrointestinal (diarrhoea).
Anthracycline-induced toxicity in this trial did not appear to be
worsened by combination with VPA, and other toxicities are
manageable providing some reassurance that any synergy in terms
of efficacy will not be replicated in unwanted side effects. A phase
II trial combining VPA with chemotherapy (5FU, epirubicin and
cyclophosphamide) is currently recruiting patients with metastatic
breast cancer (www.clinicaltrials.gov).
A number of mechanisms may account for the potentiation of
DNA-damaging agents by HDIs, reflecting their pleiotropic
actions. For topoisomerase inhibitors, HDAC1 and -2 have been
shown to bind and interact with topoisomerase II, and form an
integral part of the NuRD complex (Tsai et al, 2000). Scheduling
appears to be critical in explaining the variable potentiating effects
of HDIs on topoisomerase II inhibitors, with pre-exposure of
breast cancer cells to vorinostat for 48h needed to induce
synergistic apoptosis, increase nuclear epirubicin levels and
increase DNA damage. Shorter pre-exposure periods abrogated
synergy, and exposure after chemotherapy resulted in antagonistic
effects, implying that HDI relaxation of chromatin allows greater
access for topoisomerase II inhibition, but possibly also stabilises
the topoisomerase II–DNA complex further resulting in more
efficient generation of strand breaks. Expression of the chemo-
therapeutic target may also be crucial as potentiation was lost
in topoisomerase II null cells if the HDI was combined with
epirubicin but not topotecan (Marchion et al, 2004).
Sequencing was also important for combination with topo-
isomerase I inhibition but with apparent benefit for HDI exposure
after the chemotherapeutic to exploit cell cycle effects of each
agent. Potentiation has been shown for an HDI added 24–48h
after camptothecin in breast and lung cancer cells. Cells arrested in
G2-M by camptothecin appeared most sensitive to subsequent HDI
addition possibly through HDI-induced decreases in cyclin B levels
and of the antiapoptotic proteins XIAP and survivin. These
findings suggested that reduced expression of these antiapoptotic
factors could increase efficacy of topoisomerase I inhibitors if
given in a sequence that does not prevent tumour cell progression
through S phase (Bevins and Zimmer, 2005). Enhancement of
cisplatin-induced apoptosis by HDIs in oral squamous cell
carcinoma has also been shown to be greater if the HDI is given
concurrently or following chemotherapy rather than prior.
Experiments suggested that cells arrested at the G1/S checkpoint
by cisplatin were more sensitive to HDAC inhibition through
enhancement of reactive oxygen species generation and caspase-3
activation. Histone deacetylase inhibitor therapy decreased in-
tracellular reduced glutathione. Thus, HDIs appeared to disrupt
intracellular redox balance, inducing maximal apoptosis at G1/S
arrest and potentiating platinum response (Sato et al, 2006). Taken
together, there is mounting pre-clinical evidence that HDIs
synergistically potentiate chemotherapeutic agents that exploit
topoisomerase enzymes and DNA damage. Clinical investigation
now in progress will elucidate whether these promising findings
translate to the clinic and also if interactions impact on toxicity
(Table 1).
Taxanes, which inhibit microtubule depolymerisation during
metaphase resulting in increased microtubule formation and
activation of mitosis checkpoints leading to apoptosis, have also
been investigated in combination with HDIs. Synergistic reduc-
tions in growth were seen in endometrial cancer cells following
treatment with paclitaxel combined with the HDI trichostatin A
(TSA), and this was confirmed in mouse xenograft studies (Dowdy
et al, 2006). Synergistic interaction was also seen in breast cancer
cells combining docetaxel with vorinostat (Bali et al, 2005). There
are no published clinical data for HDI–taxane combinations but
trials are ongoing in breast and gynaecologic cancers (Table 1).
With regard to underlying mechanisms, in endometrial cancer
cell lines, TSA administration induced a-tubulin acetylation
and appeared to stabilise microtubules. Combination with
paclitaxel led to a significant increase in acetylated tubulin and
microtubule stabilisation above that with either agent alone
(Dowdy et al, 2006).
These data show a clear rationale for combining HDIs with a
range of chemotherapeutic agents, but that clinical trials must be
underpinned by a clear mechanistic rationale specific to both
experimental agents and tumour types.
HDI COMBINATIONS WITH AGENTS TARGETING THE
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR
(HER) FAMILY
Targeted therapies aimed at the HER family have advanced
treatment of a range of common malignancies including breast,
colorectal and lung cancers. The main data regarding HDI
combinations to optimise this approach are for HER2-over-
expressing breast cancer. Trastuzumab, a humanised monoclonal
antibody to the HER2 extra cellular domain, is effective for those
with receptor overexpression; however, optimisation of HER2-
targeted therapy and avoidance of resistance mechanisms are
required (Crabb and Chia, 2007). In vitro studies indicate that
HDIs have single-agent activity in HER2-overexpressing breast
cancer cell lines including attenuation of HER2 expression, its
tyrosine kinase activity, its cell membrane localisation and
dimerisation with HER3 (Fuino et al, 2003; Bali et al, 2005).
Combination with trastuzumab produced synergistic induction of
apoptosis (Fuino et al, 2003; Bali et al, 2005). Synergy may result
from counteracting HER2 overexpression as HDAC inhibition
reduced HER2 mRNA transcript expression and induced HER2
protein degradation (Scott et al, 2002; Fuino et al, 2003). The latter
mechanism occurred through the acetylation of heat shock protein
(HSP)90, causing its inactivation and loss of multiple HSP90 client
proteins. HSP90 acetylation decreased ATP binding, inducing a
shift from HER2 binding with HSP90 to HSP70, resulting in HER2
targeting for ubiquitination and proteasomal degradation (Fuino
et al, 2003). On the basis of these in vitro data, clinical trials of
trastuzumab–HDI combinations are in progress for locally
advanced and metastatic breast cancer.
It remains unproven to what degree synergism between HDIs
and trastuzumab in HER2-positive breast cancer models might
also apply to other HER2-directed therapeutics that are in various
stages of clinical testing (Crabb and Chia, 2007). However,
inhibition of proliferation, apoptosis and signalling inhibition
were potentiated when vorinostat was co-administered with the
pan-HER tyrosine kinase inhibitor CI-1033 in breast as well as
prostate and head and neck squamous carcinoma cells.
Regarding other members of the HER family, in non-small cell
lung cancer (NSCLC), synergy has been shown between HDIs and
the HER1 (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib
(Witta et al, 2006). Histone deacetylases are recruited by
transcriptional repressors such as Slug/Snail and ZEB1, which
are implicated in resistance mechanisms to these agents,
and gefitinib sensitivity appeared to be restored in NSCLC cell
line models of gefitinib resistance when combined with an
HDI (Witta et al, 2006). In a separate study, HSP90 acetylation
and reduced association with HER1, Akt and STAT3 were seen in
cell lines harbouring HER1 kinase mutations following exposure
to HDIs leading to apoptosis. Conversely, little effect on
apoptosis was seen in cells not dependent on HER1 through
kinase mutations. Therefore, HER1 mutation status might be a
predictive factor for HDI combination with HER1 inhibitors in
this setting. This highlights the value in dissecting the mecha-
nisms underlying beneficial combinations to allow for rational
targeting of appropriate cancer phenotypes early in clinical
development.
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Proteasome inhibitors act by binding within the catalytic 20S core
of the proteasome, resulting in the build-up of proteins targeted
for degradation. Cancer cells appear more likely to accumulate
misfolded proteins than normal cells, producing a therapeutic
window with promising activity in haematological malignancies.
Other evidences exist regarding synergistic interactions with HDIs.
Treating myeloma cell lines with bortezomib followed by
vorinostat produced synergistic induction of mitochondrial injury,
caspase activation and apoptosis associated with NF-kB inactiva-
tion (Pei et al, 2004). Similar findings were also observed in BCR/
ABL-positive and -negative leukaemia cell lines and, interestingly,
in solid tumour cell lines.
Combined HDAC–proteasomal inhibition may be effective
because both interact with NF-kB pathways. Proteasome inhibitors
cause accumulation of IkBa increasing its NF-kB binding, thereby
preventing nuclear localisation and activation of NF-kB target
genes. NF-kB subunits are acetylated at multiple lysine residues by
p300/CBP acetyltransferases. Acetylation of different residues
regulates different NF-kB functions (including transcriptional
activation, DNA-binding affinity, IkBa assembly and subcellular
localisation), and HDIs manipulate gene expression patterns
resulting from NF-kB activation both directly through NF-kB
subunit acetylation and indirectly through chromatin remodelling
(Chen and Greene, 2003; Graham and Gibson, 2005).
HDI COMBINATION WITH HORMONAL THERAPY
Another combination approach for targeting aberrant gene
silencing directly is with retinoic acid in acute promyelocytic
leukaemia. Acute promyelocytic leukaemia is characterised by
translocations of the retinoic acid receptor A (RARA) gene most
commonly with the PML gene. The resulting fusion protein
transcription factor has enhanced co-repressor-binding properties,
increasing HDAC and DNA methyltransferase recruitment. This
aberrant retinoid signalling results in potent transcriptional
silencing of target genes. All trans-retinoic acid (ATRA), alone
or combined with chemotherapy, is effective in reversing this
silencing but resistance may occur. Addition of an HDI to this
combination is logical in view of the enhanced co-repressor
binding and HDAC recruitment by RARA fusion proteins. Histone
deacetylase inhibitor therapy alone does not induce differentiation
in APL but can induce this in retinoic acid-resistant cell lines when
the two agents are combined (Altucci et al, 2005) In APL, this
approach requires clinical testing to prove its effectiveness over
retinoic acid treatment alone. In acute myeloid leukaemia (AML)
or myelodysplastic syndrome (MDS) either unsuitable for or
relapsed following conventional therapy, combined VPA and
ATRA has produced modest efficacy in phase I/II clinical trials
with apparently manageable toxicity. It remains unclear, from
these studies, to what extent the combination adds to either drug
given as monotherapy, and further data in this area would be of
interest (Bug et al, 2005; Kuendgen et al, 2005, 2006).
Histone deacetylase inhibitors may be of value in combination
with hormonal therapy for breast cancer. They potentiate the
antiproliferative effects of the selective oestrogen receptor (ER)
modulators tamoxifen and raloxifene, the pure antioestrogen
fulvestrant and the aromatase inhibitor letrozole in breast cancer
cell lines. Interestingly, the partial agonistic effect of endometrial
adenocarcinoma cell proliferation induced by tamoxifen was
blocked by HDI co-administration (Hodges-Gallagher et al,
2007). In a further work, treatment with an HDI rendered formerly
unresponsive ERa-negative breast cancer cells responsive to
tamoxifen. HDI enhanced overall ER transcriptional activity in
these cells. Interestingly, this appeared to be by inducing the
expression and nuclear translocation of ERb but not ERa.
Reduction of ERb expression by short interfering RNA abrogated
this HDI-induced sensitisation effect (Jang et al, 2004). Evidence
exists to suggest that DNA methylation and histone deacetylation
Table 1 A search of the NCI clinical trial database (www.cancer.gov/clinicaltrials) was conducted on 20 December 2007 (protocol search id 3988767) to
identify all clinical trials of HDIs in combination with other agents currently recruiting patients
Agents under investigation in combination with HDI
Compound Class Potency Tumour site/type Phase I clinical trials Phase II clinical trials
SAHA (Vorinostat),
Merck (Whitehouse
Station, NJ, USA)
Hydroxamate BmM MDS; MM; AML; renal;
NSCLC; colorectal; GBM;
upper gastrointestinal;
ovarian; breast
Bortezomib; bexarotene; 5-flourouracil,
leucovorin and oxaliplatin; isotretinoin;
gemcitabine; temozolamide; decitabine;
doxorubicin; idarubicin; flavopiridol;
5-azacitidine; cytarabine and etoposide;
irinotecan, 5-flourouracil and leucovorin;
docetaxel
Bevacizumab; isotretinoin;
5-flourouracil; paclitaxel and
bevacizumab; bortezomib; decitabine;
erlotinib; isotretinoin and carboplatin;
tamoxifen; carboplatin and paclitaxel,
5-azacitidine
PXD101 (Belinostat),
CuraGen (Branford,
CT, USA)
Hydroxamate BmM Lymphoma; advanced
haematological malignancy;
solid tumours; ovarian
Bortezomib; isotretinoin; 5-azacytidine;
5-flourouracil
Bortezomib, carboplatin and paclitaxel
LBH589, Novartis
(Basel, Switzerland)
Hydroxamate BnM MM; breast; solid tumours Ketoconazole; bortezomib; lenalidomide
and dexamethasone; paclitaxel, carboplatin
and bevacizumab
Trastuzumab, gemcitabine
FK228 (Romidepsin),
Gloucester
Pharmaceuticals
(Cambridge, MA, USA)
Cyclic peptide BnM MM; pancreatic; lung and
pleural
Decitabine; flavopiridol Bortezomib; gemcitabine
Valproic Acid Aliphatic acid BmM AML; CLL; small
lymphocytic lymphoma;
aggressive B-cell NHL;
MDS; melanoma; ovarian;
GBM; breast
Decitabine; etoposide; bevacizumab Karenitecin; 5-azacytidine and ATRA;
carboplatin and 5-azacytidine;
temozolamide and external beam
radiotherapy; 5-flourouracil, epirubicin
and cyclophosphamide
MGCD0103,
Methylgene (Montreal,
QC, Canada)
Benzamide BmM MDS; AML; solid tumours Docetaxel 5-azacitidine, gemcitabine
AML¼acute myeloid leukaemia; ATRA¼all-trans retinoic acid; CLL¼chronic lymphocytic leukaemia; GBM¼glioblastoma multiforme; HDI¼histone deacetylase inhibitor;
MDS¼myelodysplastic syndrome; MM¼multiple myeloma; NHL¼non-Hodgkin’s lymphoma; NSCLC¼non-small cell lung cancer.
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promoter. Inhibition of either may be sufficient to activate the
silenced ER gene (Zhou et al, 2007). Clinical investigation
following these observations is in progress.
HDI COMBINATION WITH TARGETED AGENTS FOR
BCR/ABL-POSITIVE LEUKAEMIA
The role of HDIs in combination with agents targeting the BCR/
ABL oncoprotein has been investigated in chronic myeloid
leukaemia (CML) for which the BCR/ABL tyrosine kinase inhibitor
imatinib is now a standard therapy but resistance can develop. In
vitro, vorinostat has been shown to synergistically enhance the
activity of imatinib and the second-generation agent dasatinib
possibly through the inhibition of HSP90 chaperone function. In
addition to downregulation of BCR/ABL expression, multiple
perturbations in signalling and cell cycle-regulatory proteins are
induced by this combination including the Ras/Raf/MEK/ERK,
Akt, STAT and JNK pathways and cyclin D1 (Yu et al, 2003).
Subsequently, combination of HDI with sorafenib, an inhibitor of
multiple kinases including Raf-1, platelet-derived growth factor,
vascular endothelial growth factor receptors 1 and 2, and FLT3,
was found to induce synergistic cell death in BCR/ABL-positive
cells, imatinib-resistant cells and primary CD34þ bone marrow
cells from CML patients (Dasmahapatra et al, 2007).
Interestingly, both imatinib and sorafenib blocked the HDI-
mediated induction of p21
WAF1/CIP1, perhaps the most consistently
observed HDI downstream molecular effect. Forced expression of
p21
WAF1/CIP1 depleted the combined HDI/sorafenib effect, imply-
ing that this may be required for synergism. Potential mechanisms
include disruption of p21
WAF1/CIP1-mediated G1 arrest, interfer-
ence with its direct antiapoptotic actions such as inhibition of
caspase-3 or c-Jun NH2-terminal kinase activation or disruption of
the upstream Raf/MEK/ERK axis (Yu et al, 2003; Dasmahapatra
et al, 2007).
HDIs IN COMBINATION WITH OTHER EPIGENETIC
MODIFIERS
One reason for the relatively modest number of genes affected by HDIs
is the dominant effect of methylation status over acetylation. Dual
administration of HDIs with DNA-hypomethylating agents is therefore
of interest. Aberrant DNA methylation is characteristic of a number of
myeloid leukaemias (Garcia-Manero et al, 2002) and dual epigenetic
modulation might allow suppression of the malignant clone. In vitro,
the combination of VPA and 5-aza-20-deoxycytidine (decitabine)
produced synergistic growth inhibition and induction of apoptosis in
leukaemia cell lines (Yang et al, 2005). In a subsequent phase I/II
clinical trial of this combination, 54 patients with AML or high-risk
MDS, either relapsed or unsuitable for first-line chemotherapy, received
a fixed dose of decitabine and escalating doses of VPA. Twelve patients
(22%) had objective responses with 10 complete remissions. Major
cytogenetic response was documented in six of eight responders. Of the
five target genes investigated, hypomethylation of the key cell cycle-
regulating gene, p15 was found to be the best indicator of response.
Pretreatment p15 methylation was significantly lower in responders vs
non-responders; however, neither the absolute or the percentage
change in p15 methylation was statistically significant, and responses
were not correlated with the induction of H3 or H4 acetylation (Garcia-
Manero et al, 2006). In another study, utilising phenylbutyrate and 5-
azacytidine in a similar patient population, 11 of 29 patients responded.
Furthermore, six of six with pretreatment methylation of p15 or CDH-1
(E-cadherin) promoters reversed methylation during the first cycle of
therapy whereas none of the six non-responders showed any
demethylation (Gore et al, 2006). Further identification and validation
of predictive biomarkers would be of immense value in the ongoing
clinical assessment of HDIs in this and other settings but may need to
be tumour- and combination-specific. Toxicity in these clinical studies
included neurological (encephalopathy, confusion, somnolence) and
haematological (thrombocytopaenia, neutropaenia) events and fatigue,
but the combinations were considered well tolerated. Further clinical
evaluation will be required to establish the value of combination
therapy over monotherapy approaches and compared to conventional
chemotherapeutic interventions.
HDI COMBINATION WITH IONISING RADIATION
Histone deacetylase inhibitors can act as radiosensitisers (Kara-
giannis and El-Osta, 2006). For example, in NSCLC cells, synergism
has been demonstrated between HDIs and irradiation for induction
of apoptosis and inhibition of clonogenic survival and confirmed in
in vivo tumour studies. Following irradiation, g-H2AX foci following
irradiation, a conserved response to DNA double-strand break
formation necessary for recruitment of many factors involved in
DNA repair was found to be increased by combination with an HDI.
Furthermore, radiation alone induced translocation of HDAC4 to
the nucleus whereas combination therapy resulted in its confine-
ment to the cytoplasm (Geng et al, 2006). The DNA damage-sensing
protein, 53BP1, has been shown to co-localise to the nucleus with
HDAC4 in response to double-strand DNA breaks (Kao et al, 2003).
Therefore, HDI therapy may potentiate radiation in part by the
suppression of HDAC incorporation into DNA damage-signalling
and -repair complexes. Other factors are also likely to be relevant.
For example, following DNA damage, checkpoint molecules activate
ataxia telangiectasia-mutated protein (ATM), which in turn
phosphorylates effectors. Histone deacetylase-1 is known to interact
with ATM and this interaction is enhanced by ionising radiation and
inhibited by HDAC inhibition (Kim et al,1 9 9 9 ) .H i s t o n e
deacetylases are also important for the repair of established
double-strand breaks, with the expression of Ku70, Ku86 and other
repair proteins decreased by HDI therapy despite radiation-induced
DNA damage (Munshi et al, 2005). These pre-clinical studies
demonstrate the range of potential mechanisms that are implicated
in HDI-mediated radiosensitisation and a variety of clinical studies
are in progress (Table 1).
CONCLUSIONS
The niche for HDIs in the treatment of cancer remains inadequately
defined. Understanding of the diverse mechanisms for their anticancer
action continues to increase, including molecular mechanisms
elucidated by studying combination therapy. In the face of modest
activity as single agents, except in cutaneous T-cell lymphoma (CTCL)
where the unique tumour microenvironment may account for their
unpredicted efficacy, their ability to synergise with, and potentially
overcome resistance to, many other agents represents a promising
strategy for clinical development. Current evidence to support this
assertion is predominantly pre-clinical, with only a small number of
non-randomised early-phase clinical trials reported (of combinations
with anthracyclines, ATRA or DNA-hypomethylating agents). We
therefore wait for clear proof that the multiple promising combinations
tested in pre-clinical studies can in fact translate to added clinical value
for patients above use of single or other agents. If this can be achieved,
then the next few years should herald clinical data from phase II and III
studies to define the exact value of combination approaches and
improved understanding of mechanisms that underpin activity.
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